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Toxicity Tests in Animals: Extrapolating to
Human Risks
Editor's Note: This article is the third ofa
three-partseries on the use ofanimal models
in toxicity testing. Thefirstpart explored
traditionaluses ofanimals in toxicity testing;
the secondpart discussed the use ofalterna-
tive to animal models in human risk assess-
ment.
Controversy continues to be a part oftoxi-
city testing in the United States and else-
where. The usefulness ofanimal results for
predicting human risks and whether ani-
mal tests should be used at all are just two
ofthe contentious issues that have pit sci-
entists, industry representatives, govern-
ment regulators, and environmentalists
against each other.
The economic, social, and political
stakes are enormous. Industry spends hun-
dreds ofbillions ofdollars to comply with
regulations for minimizing risks to work-
ers and the environment, for health care
for those affected by exposure to toxic
materials, and for litigation costs. Lawsuits
over dioxin exposure alone (induding the
infamous Agent Orange lawsuits from the
Vietnam War) are still pending, with a
potential price tag of $500 billion for
eventual settlements. Many chemicals
released into the environment are not test-
ed at all. Therefore, it is imperative to
determine the most accurate, efficient, and
cost-effective ways of assessing risks to
humans.
Given the importance of toxicity test-
ing and regulation and the furor surround-
ing these activities, the responsibility of
the scientific community to help shape
reasonable solutions becomes paramount.
To do this, science must offer solid data or
the best approximations of risks of envi-
ronmental exposures to inform other are-
nas (e.g., political, social, economic) that
determine the direction of social policy.
Science must seek to answer the questions
ofwhether a substance is toxic; ifso, what
are the mechanisms oftoxicity; how much
exposure makes it toxic; and what are the
best methods for estimating risk.
One indisputable fact is that thewhole-
animal model is still the most widely used
method for assessing potential toxicity
risks to humans. This is true whether the
testing is designed to measure the carcino-
genicity of an environmental hazard such
as pesticides or the potentially toxic effects
of a new drug used to treat a human dis-
ease. Alternatives to animals are being
developed, but animals still play the main
role as research subjects in human risk
assessment [see Part 2 ofthis series in EHP
101(4)].
The efforts ofthe scientific community
to defend the use of animal models are
undergirded by the belief that there are
many similarities between species, which
supports the use ofanimal tests to predict
effects in humans. For example, in 1975
Schmidt-Nielsen published in the Journal
ofExpeimentalZoology a summary of the
biological and biochemical similarities
between species, including cell structure,
energy metabolism, and transmission of
genetic information. These similarities
appear despite the more obvious dissimilar-
ities in size, weight, and other factors
between, for example, a laboratory mouse
and ahuman. The principle underlying the
use ofanimal tests for human
risk assessment is often re-
ferred to as the principle of
phylogenetic continuity.
Animal to Human
Extapolations
Nonetheless, animal-to-hu-
man extrapolation has its
problems. There are a variety
ofdifficulties faced by regula-
tory agencies that attempt to
use results of animal studies
to predict human risks.
Gerhard Winneke and JudiWeissin
Hellmuth Lilienthal at the mustjustifyso
Heinrich-Heine University in toestimate ris
Dusseldorf, Germany, have
pointed to differences in neurotoxicity test-
ing between rodents and primates. John
Caldwell at St. Mary's Hospital Medical
School in London has stated that inter-
species differences in metabolism may be
the single most complicating factor in
using animal toxicity data to identify
human hazards. In 1992, Caldwell evaluat-
ed earlier research on the liver to toxicityof
the food flavoring agent cinnamyl anth-
ranilate, which had been used since the
mid-1930s, andwas identified in 1980 as a
potent liver carcinogen in mice. More
detailed subsequent testing showed signifi-
cant differences in carcinogenic effects
between mice and rats, however, and even
more differences in metabolism when vol-
unteer human subjects were used. Event-
ually, a ban against cinnamyl anthranilate
use was lifted because the animal-to-
er-
elect
;ks.
human interpretation was found to be
unreliable.
Caldwell holds hope for the increasing
use of "designer" animal species wherein
gene transfer could produce laboratory ani-
mals bred for specific physiological and
genetic traits [see "The Use ofTransgenic
Mice for Environmental Health Research,"
EHP 101(4)]. Although he believes that
toxicology poses special problems for the
use ofgenetically modified animals, such as
the complexity of metabolic pathways of
toxic chemicals, he believes it may lead to
animal models with far more predictive
power for human risk assessment than we
have today.
Despite such reports, scientists in vari-
ous fields have found more advantages
than disadvantages in using animal data to
predict risks to humans. For example, Judi
Weissinger, formerly at FDA's Center for
Drug Evaluation and Research, and now at
Glaxo, examined numerous research stud-
ies involving animal-to-
20 human safety evaluation
z interpretations for drugs.
Weissinger identified sever-
al well-known drugs for
which cross-species results
are available. Animal data
were considered in formu-
lating the dose and experi-
mental design for the hu-
man trials for all of these
drugs. In most cases, the
animal finding predicted
effects in humans.
-Researchers Some effects observed
tion ofspecies with animals in the studies
reviewed by Weissinger oc-
curred in exposed humans
even when toxicological tests with a small
number of human subjects did not detect
these effects. For example, in the case of
methotrexate, used to treat bone cancer
and rheumatoid arthritis, animal tests
showed liver toxicity effects. Direct tests
of human liver function failed to detect
toxic effects, which were shown later from
liver biopsies. In contrast, however, a test
of another unapproved drug gave com-
pletely different results in animals and
humans.
Weissinger's main point is that it will
always be up to the researcher to take into
account toxicodynamic factors to justify
selection of the animal species and the
validity of the animal-to-human predic-
tion. Although her findings concern drugs
rather than environmental toxins, there are
some similarities in the approaches taken
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by FDA and those taken by EPA. Weis-
singer notes, "FDA's Center for Food
Safety and Applied Nutrition is one ofthe
FDA centers that uses a quantitative risk
assessment similar to that ofEPA."
Maximum Tolerated Dose
It is not economically feasible to test chem-
icals at low doses because enormous num-
bers ofanimals would be required to detect
statistically significant increases in cancer
incidence. Therefore, it is essential that
higher doses are used to determine whether
a chemical is a carcinogen. However, the
use ofhigh doses to assess human risks has
frequently been debated. Usually, the
experiments are done in rats and mice at
the highest dose that will not shorten the
life of the animals but that is expected to
cause them to gain 10% less weight than
control animals. This dose is known as the
MTD (maximum tolerated dose), and the
studies frequently use the MTD and 1/2
MTD. To estimate human risk at expo-
sures to the chemical that are frequently
thousands of times lower
than the MTD, a linear ex-
trapolation is used. The
MTD is used to give the
greatest chance of observ-
ing an effect of the chemi-
cal in animals. Linear ex-
trapolation is used to ob-
tain a hypothetical, maxi-
mum risk to humans at
various exposure levels,
including especially low
exposure levels, as a basis
for regulatory policy.
However, "testing for Lois Gold-Use
carcinogenicity in animals ficientto predict
at near toxic doses does not
give enough information to predict the
excess number of cancers from low doses
typically experienced by humans," said Lois
Gold, director ofthe Carcinogenic Potency
Database Project at Lawrence Berkeley
Laboratory. Gold has serious reservations
about the effects at the MTD because high
dosing may increase the number oftumors.
"Near-toxic doses can frequently cause cell
division due to cell killing and consequent
cell replacement, and these effects can be
unique to high doses. Cell division itself
can increase the chance of mutations and
tumors, and then the effects at low doses
are likely to be much less than a linear
model would predict and may often be
zero. It is important to add measurements
of cell division to animal cancer tests and
"to use the results to estimate low-dose risks
more adequately," said Gold.
In response to criticism ofthe continued
use ofthe MTD in long-term carcinogenesis
bioassays, it has been pointed out that the
MTD is often misunderstood and more
of M
low
complex than is realized. James Huffofthe
Environmental Carcinogenesis Program at
NIEHS stresses that the definition of the
MTD concept written in 1976 by the
National Cancer Institute is still as good and
relevant today as it was then. Yet, most peo-
ple seem to single out the
"body weight reductions"
aspect and rarely explore the
many other scientific facets
of the working definition.
Huff insists that many addi-
tional factors, such as weight
gain or loss, dinical and bio-
chemical signs of toxicity,
organ weights and function,
absorption, distribution, and
excretion characteristics, go
into the selection of the
MTD. This prospective esti-
mate should be viewed as a James Huff-W
guide rather than as an ab- ue to use MTDI
solute. to humans.
"Still, to minimize possi-
ble risks to humans and specifically to iden-
F::''- tify potential carcinogenic risks
fN for humans," Huff said, "we
0 should continue to use the
: MTD concept for evaluating
the carcinogenic potential of
chemicals in laboratory ani-
mals." Doubts about the per-
fection of the MTD should
not be the cause to change
these dose-response studies or
to alter the experimental iden-
tification and measurement of
potential human risks using
animal models. Instead, such
ITD not suf- concerns should be taken into
-dose risks. account when applying the re-
sults during the preliminary
stages of the risk assessment process while
also using all other available data on the
chemical.
This was also the recommendation of
the National Research Council of the Na-
tional Academy ofSciences, which advocat-
ed continued use ofthe MTD in the overall
strategy for toxicity testing in a report
released in February. In a split decision, a
majority of the council recommended that
metabolic and physiologic studies be con-
ducted when initial test results at the MTD
warrant further study. A third of the panel
disagreed, arguing that such studies should
be conducted first and then dose regimens
established on the basis of the results. It
appears that the MTD approach of testing
chemicals in animals will continue to be an
integral part of predicting potential cancer
risks to humans.
Ve si
to n
Dose-Response Relationships
Perhaps most controversial is the basic
question of the methods used to estimate
human risks from animal testing data. This
is particularly true regarding the hazards
posed to humans by chemicals that might
cause cancer, whether exposure occurs in
the general environment, the workplace, or
the home. Two different methods, with
quite different results for pre-
I dicting risks for humans, are
Z the mostwidely used.
The first method, referred
to as the "safety factor ap-
proach," has been in use in
the United States since the
1930s. At that time, when
pesticides were beginning to
be viewed as possibly danger-
ous for humans as contami-
nants in the food supply, a
method was needed to estab-
lish the maximum amount
hould contin- humans could be exposed to
ninimize risks without risk. Settinga toxicity
threshold for the amount of
the dangerous substance was
difficult, given the size ofthe human popula-
tion and various sensitivities of different
groups to the same substance. So, howcould
one extrapolate test data from a few animals
to all those humans?
A solution proposed in the 1950s by
Arnold Lehmann of the FDA was to use a
100-fold safety factor. Lehmann proposed
first determining a threshold dose level,
beyond which a substance was toxic for ani-
mals. Then he divided that amount of the
substance by 10 because of the assumption
that some people might be more sensitive to
the substance than animals. Next, he divided
the smaller level by 10 again, since some
people might be more sensitive than other
people. The result was a 100-fold lower
amount of the substance as an acceptable
exposure level forpeople.
Also in the 1950s, William Huper pro-
posed an alternative way ofestimating risks
to humans from carcinogens. This alterna-
tive approach generally is referred to as the
linear model, in which the risk to humans
is estimated from the dose-response rela-
tionship in animals. The risk is viewed as
proportional to what was observed in ani-
mals given high doses of the substance.
Huper postulated that carcinogens can
damage DNA leading to mutations in cells
representing an early but necessary step in
the development of cancer. According to
the generally accepted theory, these geneti-
cally altered cells would grow more rapidly
than normal cells, eventually producing a
tumor many years after the chemical expo-
sure had occurred. Since a single mutation
could theoretically cause a tumor, there
would be no safe level of a carcinogen.
Support for this model has been provided
by evaluation of cancer risk in people
exposed to varying levels of radiation and
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some chemicals that cause mutations in
cells. There is little disagreement among
scientists and regulatory officials that risks
for those chemicals that cause cancer by
increasing the mutation frequency ofcriti-
cal target genes should be estimated using
linear models. However, some feel that
those chemicals which are carcinogens
because they increase the expansion of
genetically altered cells or induce mutant
cells by indirect mechanisms should be
regulated by a safety factor approach. Still
others argue that the growth rate ofgeneti-
cally altered cells can be enhanced by many
different mechanisms and in some of those
cases, receptor-mediated increases in cell
division for example, a linear model might
not be most appropriate. In addition, said
Carl Barrett, chief of NIEHS's Laboratory
of Molecular Carcinogenesis, "chemicals
acting by mutagenic mechanisms exhibit
nonlinear dose responses. Therefore, the
dose response of each chemical must be
determined, and it is not possible to assume
nonlinear responses on the basis ofputative
mechanisms, for example, genotoxic or
nongenotoxic."
The safety factor approach, where the
toxic dose in animals is divided by at least a
factor of 100 to estimate human risk levels,
is favored by some and strongly opposed by
others. "I don't really see anything happen-
ing to resolve the differences between these
two models," said Joseph Rodricks, director
of health sciences at the consulting firm
Environ. "We shouldn't be looking at ways
to estimate risks that depend on whether the
substance is a carcinogen or a noncarcino-
gen anyway. Instead, there is evidence that
suggests there may be carcinogens that have
thresholds and those that do not. We
should be looking at the underlying biologi-
cal mechanisms to determine the most
appropriate models for assessing human
risks.
Rodricks added that since there is no
direct way to measure the exact threshold
for human risks (especially at the low doses
often experienced by humans), agencies like
EPA, FDA, and OSHA have taken the cau-
tious approach (using the more conservative
linear models) to estimating levels ofa sub-
stance that might be toxic to humans, "until
someone can prove differently."
"The safety factor approach is subjective
and does not use all of the available infor-
mation when establishing a safety level,"
said Christopher Portier of NIEHS. "This
approach fails to consider the observed pat-
tern ofresponses, whereas the evaluation of
dose-response relationships permits incor-
poration ofbiological data."
Portier highlighted the research design-
dependency problem of the studies that are
used in the safety factor approach. Because
the number ofanimals used in such studies is
often small (e.g., 10-50 per group), simply
increasing the sample size will increase the
chance of finding statistical significance
between groups. For example, if a specific
dose is given to a group of 10 animals, 3 may
develop a tumor, and 1 ofthe 10 control ani-
mals may also develop a tumor. A statistical
test comparing the two groups might not
find the 1-in-10 versus 3-in-10 result to be
statistically significant. Ifthe sample sizes are
increased to 100, and the same proportions
hold true, 30 of the experimental animals
will develop a tumor versus 10 in the control
group. That difference in numbers would
likelybestatistically significant.
The point of Portier's argument is not
that all studies should use more animals, but
that the safety factor approach may be
flawed. Just changing the sample size could
yield a completely different result, although
the underlying slope of the response curve
for the substance would be the same.
The implications ofwhich model to use
are significant. For example, the govern-
ment-regulated safetyexposure level ofdiox-
in varies greatly from country to country. In
fact, some countries allow more than 1000
times the acceptable U.S. levels, even
though the same data (liver tumors in
female rats) were used worldwide to esti-
mate risks. Differences are caused by the
selection ofthe models to predict the risks.
Dose-response modeling is slowly
becoming more common, and an effort is
underway at both NIEHS and EPA to eval-
uate past studies to more carefully define
dose-response relationships. It is possible
that this collaborative agency effort may
begin to shed light on the controversy ofthe
safety factor versus linear dose-response
models.
MolecularToxicologyand the Future
The emerging field ofmolecular toxicology
is cited by several leading scientists in the
field as holding promise for the future of
human risk assessment. Using molecular
biology methods to evaluate markers of
toxic response may offer a more accurate
way ofassessing human risks.
Molecular toxicology has also been use-
ful in animal-to-human risk extrapolations.
For example, laboratory mice used by NTP
researchers for testing substances that
might cause liver tumors in humans have a
background rate of liver tumors of about
20-30%. When using data from such ani-
mals, researchers must be able to separate
out these "normal" tumors from ones that
might be caused by the substance being
tested. If liver tumors increase in these
mice during a test, it is not immediately
clear whether the substance simply in-
creased their already heightened suscepti-
bility to liver tumors or actually introduced
a new risk.
By sequencing the ras oncogene in the
tumors of such mice, NIEHS researchers
uose
Biomarkers and uncertainty in risk assessment. Experimental data obtained at high doses must be
extrapolated to predict effects at low doses, which can produce uncertainty. Biomarkers that can often
be quantified in the low dose region are useful in estimating the shape ofthe dose-response curve.
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detected pattern differences between exper-
imental and control animals. That is, some
liver tumors in animals receiving the same
chemical show the same pattern in the
oncogene as do control animals, but other
tumors show patterns unique to the chemi-
cally exposed animals. Therefore, the
unique mutation pattern in the tumors
strongly suggests that the test substance did
more than just stimulate an existing pro-
clivity toward tumor growth. Seldom is
one such test conclusive, but molecular
toxicology is a powerfil tool for estimating
risks for humans, whether in direct human
studies or in animals.
"It is extremely important to pursue
recent advances in molecular biology to
enhance our understanding ofcomparative
toxicology," said William Farland of EPA.
"This will help us make use of the animal
tools that are available for evaluating
human risks. EPA is interested in getting
the most out of animal tests to predict
human risks. We cannot just look at toxi-
cologyendpoints anymore," he added.
According to Barrett, "Studies ofmole-
cular carcinogenesis support the concept
that carcinogenesis is a multistage, multi-
causal, and multimechanistic process.
Attempts to develop simple models for this
complex process will probably fail. If any-
one pronounces that they know the mech-
anism of a carcinogenic agent, my guess is
that they will be proven wrong, because
most, if not all, carcinogens will operate
through multiple mechanisms. The dose-
response curve for the chemical will be dif-
ficult to predict because the rate-directing
mechanism may be more important than
the most obvious mechanism."
The use ofmolecular toxicology in risk
assessment has been addressed by the pres-
tigious International Agency for Research
on Cancer (LARC), based in Lyon, France.
In 1991, IARC assembled a working group
composed of leading cancer researchers
from a variety ofdisciplines. This working
group came to the following consensus:
When the available data on mechanisms are
thought to be relevant to evaluation of the
carcinogenic risk of an agent to humans,
they should be used in making the overall
evaluation, together with the combined evi-
dence for animal and/or human carcino-
genicity. It is not possible to elaborate defin-
itive guidelines for all possible situations in
which mechanistic data may influence evalu-
ation of carcinogens. The following scenar-
ios are illustrative of the range of options
available. First, information concerning
mechanisms ofaction may confirm a partic-
ular level ofcarcinogen classification as indi-
cated on the basis ofepidemiological and/or
animal carcinogenicity data. Second, for a
particular agent, strong evidence for a mech-
anism of action that is relevant to carcino-
genicity in humans could justify 'upgrading'
Development ofbiologically based risk assessment models. Data from multiple sources are used to con-
struct models. Knowledge gaps are identified, which when filled lead to refined models with less uncer-
tainty.
its overall evaluation. Third, an overall eval-
uation of human cancer hazard on the basis
of animal carcinogenicity data could be
downgraded by strong evidence that the
mechanism responsible for tumor growth in
experimental animals is not relevant to
humans. In keeping with the goal of public
health, priority must be given to the demon-
stration that the mechanism is irrelevant to
humans.
According to James Swenberg of the
Laboratory of Molecular Carcinogenesis
and Mutagenesis at the University of
North Carolina at Chapel Hill, it is be-
coming clear that the scientific and regula-
tory communities are becoming more
comfortable with using molecular data in
the risk assessment process. Draft guide-
lines on cancer risk assessment being devel-
oped by the EPA place renewed emphasis
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on incorporating mechanistic information
into the risk assessment process. Under
these proposed guidelines, straight mathe-
matical extrapolation of risk is relegated to
a default position to be used in the absence
of mechanistic data. Examples of potential
uses of mechanistic data include under-
standing the roles of metabolic activation,
detoxification, DNA repair, cell prolifera-
tion, and receptor-mediated responses in
high to low dose, route to route, and species
to species extrapolation, as well as genetic
predisposition ofanimals and individuals to
these and related processes relevant to car-
cinogenesis. The extent ofuncertainty asso-
ciated with straight mathematical risk
extrapolation should clearly be reduced by
turning to such biologically based methods
forpredicting carcinogenic risks.
The role of animals in predicting hu-
man risks probably will continue to be vital.
Although the use ofanimals as research sub-
jects has its limitations, no completely suit-
able substitute has been found. "The results
from research using animals must be inter-
preted cautiously and in light of any other
data on the compound," said I. Bernard
Weinstein, director of the Columbia-
Presbyterian Cancer Center in New York.
"But, despite the criticism, we should not
abandon long-term rodent bioassays used as
a screen for potential carcinogens in hu-
mans. Criticisms ofthis approach are over-
done, and the National Toxicology Pro-
gram, which does most ofthe rodent bioas-
says, interprets findings cautiously and is
aware ofthe pitfalls."
Weinstein pointed to the most impor-
tant consideration in the animal-to-human
leap: does the approach help humans?
"Using the animal model has been useful in
predicting certain human carcinogens in the
past. For example, vinyl chloride and
diethylstilbestrol were identified as carcino-
gens in rodents years before they were final-
ly found to be carcinogens for humans."
This approach is not only relevant for
the past, but perhaps for the future as well.
"There is a controversy now regarding cer-
tain pesticides and herbicides. They have
already been proven positive as carcinogens
for rodents. This has alerted epidemiologists
that they might be carcinogenic for humans
as well, and recent epidemiologic studies
indicate that this may be the case," Wein-
stein said. "Since almost all known human
carcinogens are also carcinogenic for ro-
dents as well," Weinstein's warning suggests
that abandoning the animal model now
may be tantamount to throwing out the
babywith the bathwater.
Teamwork and aContinuum ofRisk
and Prevention
In addition to the call for multiple data
resources, many groups are taking a stance
Social Science and
Environmental Risks
The increasing complexity of assessing risks in humans, including recent develop-
ments in genetic research and molecular epidemiology, requires more interdiscipli-
nary efforts than ever before. The push to combine expertise from multiple fields has
been advocated by such leading figures in environmental studies as Roger McClellan,
president ofthe Chemical Industry Institute ofToxicology.
McClellan believes that most ofthe easy problems have already been solved. The
difficult remaining problems will require teams of researchers from various disci-
plines, but biological scientists often find that partnership difficult to achieve (see
EHP, 101:26-29).
Whatever challenges biological scientists ma face in forging such teams (includ-
ing the problem posed by funding sources that restrict the activities they will sup-
port), scientists need not feel alone in their dilemm Their research colleagues in the
social sciences face sii;lar challenges as they study other parts ofthe "human equa-
tion in environmenta riskassessment.
Psychologists in particular have been studying perceptions of risk by humans,
their reactions to such perceptions, and factors that influence human behavior after
exposure (or suspected exposure) to carcinogens and toxic materials in the environ-
ment. While some of this interest on the part of U.S. social scientists may have its
roots in the burgeoning environmental awareness and activism ofthe 1960s, it has
more recently focused on health risks posed by the same chemicals or materials being
studied by biologists, chemists, and others in the biomedical sciences.
The fact that exposure to toxic agents is not randomly or uniformly distributed
in the United States but is instead often concentrated in minority and low-income
communities, means that cultural, sociological, and psychological factors may deter-
mine how laboratory results are used in society.
The social science literature has seen an increase in research findings related to
human risk assessment that is at least analogous to the increase seen in the biomedical
literature. Forexample, in theJune 1993 AmercanPsychologist E. Vaughan described
how different groups of human subjects have adapted differently to environmental
hazards. ("Individual and Cultural Differences in Adaptation to Environmental
Risks," pp. 673-680). She also argued for the use ofsuch data by public policy mak-
ers in forming or changing regulations that affect environmental controls, thus
implicitlyarguing for cross-discipline collaboration
In thesame vein,A.H. Wandersman and W.K Hallman examined the pitfalls of
focusing exdusively on quantitative risk assessments when the "human' dimension
dearly shows more vagaries than the controlled lab ("Are People Acting Irrationally?"
AmericanPsychologist; June 1993, pp. 681-686). In attempting to measure fearofcan-
cer and resultant human behaviors, the authors approached the question of how
much toxicity is too much? from a totally different perspective than, for example, a
biologist orchemistmight have used in alab.
In otherwords, no matterwhat acceptable level ofexposure to asubstance might
be established byregulation, based on laboratory studies withvanrous dose levels, any
level may be too much for the imdividual who learns ofit. Therefore, the decsion of
what substances must be studied, how the related research will be funded, who will
support such funding, andwhat will be done with research findings may be driven by
human fears and needs as much as byscientific curiosityand method.
If so, the call for interdisciplinary studies made by McCIlean and others may
well indude the social and behavioral sciences as well as the biomedical sciences. If
such a goal becomes important enough, the academic, research, and industry seg-
ments ofsociety may engage in a complex partnership never seen before. Given the
increasing scrutiny being levelled at many health science research budgets, it may be
that such apartnership will notbe aluxury, but an indispensable mechanism forpub-
lic support.
Dennis Maloney
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for more cooperation be-
tween academia, industry,
and the government. Roger
McClellan of the Chemical
Industry Institute of Tox-
icology highlighted the
need for cooperative efforts
by many different scientific
disciplines in toxicology
testing by using the concept
of a continuum of risk.
This continuum begins at
the basic assessment level
and extends up to and in-
cludes prevention of risks
to humans.
"If we look at environ-
mental and occupational health issues, we
can look at a four-stage process," McClellan
said, "covering source, exposure, tissue dose,
and response," each ofwhich requires the
input and expertise of scientists and other
professionals from many different disci-
plines. The challenges posed by this continu-
cii
L. Bernard Weinstein We
should not abandon long-term
rodent bioassays.
um, McClellan noted, aside
from the sheer logistical prob-
lems in having many disci-
plines routinely interact,
include the problems caused
by the different jargon used by
the professionals. Even when
using the samewords, different
scientists don't always mean
the same things. "We need to
find ways to get these different
disciplines working together,"
McClellan added.
The need for such collabo-
ration is increasingly recog-
nized in the government sector
as well. Speaking at CIIT's
annual meeting in May, Michael Taylor,
deputy commissioner for policy, FDA,
stressed the need forsuch cooperation. FDA
conducts collaborative research, as well as
establishes advisory committees with repre-
sentatives from outside the agency. Other
major federal agencies such as EPA have
developed similar mechanisms to facilitate
communication between government,
industry, and academia.
Such interaction between scientists,
industry leaders, and government policy
makers can only help bridge the gap be-
tween results found from animal toxicology
tests and subsequent predictions ofrisks for
humans. Leaping that gap is not impossi-
ble, but it is difficult. Advances with cell
and tissue cultures, computer modeling,
and genetic research continue to help
reduce the need for animals to test sub-
stances that can harm humanity, but the
advances probablywill not totally eliminate
that need. As long as we value human life,
that need will persist as scientists continue
trying to ensure that the contributions
made by such animal research subjects lead
to practical benefits for a healthier society
in a less risky environment.
Portions ofthis article were provided by Dennis M.
Maloney, president ofThe Deem Corporation.
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